Limits...
Transplantation of expanded bone marrow-derived very small embryonic-like stem cells (VSEL-SCs) improves left ventricular function and remodelling after myocardial infarction.

Zuba-Surma EK, Guo Y, Taher H, Sanganalmath SK, Hunt G, Vincent RJ, Kucia M, Abdel-Latif A, Tang XL, Ratajczak MZ, Dawn B, Bolli R - J. Cell. Mol. Med. (2010)

Bottom Line: In contrast, transplantation of expanded but untreated VSEL-SCs did not produce appreciable reparative benefits.Counter intuitively, the mechanism whereby such pre-incubation confers therapeutic efficacy does not involve differentiation into new cardiac cells.These results support the potential therapeutic utility of VSEL-SCs for cardiac repair.

View Article: PubMed Central - PubMed

Affiliation: Institute of Molecular Cardiology, University of Louisville, Louisville, KY, USA.

Show MeSH

Related in: MedlinePlus

Impact of cell therapy on cardiomyocyte hypertrophy and LV mass. (A)–(C) Representative images of cardiomyocytes in the viable myocardium from Masson’s trichrome-stained sections of hearts of mice that were given vehicle (group I) (A), expanded and untreated VSEL-SCs (group II) (B) and expanded pre-incubated VSEL-SCs (group III) (C). (D) Quantitative assessment of myocyte cross-sectional area in groups I–III compared with non-infarcted control hearts. (E) Compared with group I, echocardiographically estimated LV mass was significantly less in group III. Data are means ± S.E.M. n= 7–11 mice/group. (E) *P<0.05 versus vehicle (final); #P < 0.05 versus respective baseline values.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3064954&req=5

fig06: Impact of cell therapy on cardiomyocyte hypertrophy and LV mass. (A)–(C) Representative images of cardiomyocytes in the viable myocardium from Masson’s trichrome-stained sections of hearts of mice that were given vehicle (group I) (A), expanded and untreated VSEL-SCs (group II) (B) and expanded pre-incubated VSEL-SCs (group III) (C). (D) Quantitative assessment of myocyte cross-sectional area in groups I–III compared with non-infarcted control hearts. (E) Compared with group I, echocardiographically estimated LV mass was significantly less in group III. Data are means ± S.E.M. n= 7–11 mice/group. (E) *P<0.05 versus vehicle (final); #P < 0.05 versus respective baseline values.

Mentions: Because post-infarct LV remodelling is associated with myocyte hypertrophy and increased LV mass, we investigated the effects of VSEL-SC therapy on these parameters. To this end, we compared the three infarcted groups (groups I–III) with a separate control group (n= 6) of non-infarcted mice that were of similar age (10–12 weeks) and did not undergo surgery. Although the differences did not reach statistical significance, in infarcted mice treated with vehicle (group I) or expanded but not pre-incubated VSEL-SCs (group II), the cross-sectional myocyte area at 35 days after MI (219 ± 21 μm2 and 188 ± 31 μm2 in groups I and II, respectively) was 48% and 27% higher compared with non-infarcted control mice (148 ± 16 μm2). However, in mice given expanded and pre-incubated VSEL-SCs (group III), the myocyte area (147 ± 17 μm2) was virtually identical to that in non-infarcted mice and 30% smaller than that in group I (Fig. 6). These results were corroborated by the echocardiographic estimates of LV mass, which were significantly increased from baseline to 35 days in groups I and II but not in group III; in the latter group, the LV mass was 24% smaller than in group I (P<0.05) (Fig. 6E). Together, these data indicate that transplantation of expanded and pre-incubated VSEL-SCs is associated with attenuation of myocyte hypertrophy.


Transplantation of expanded bone marrow-derived very small embryonic-like stem cells (VSEL-SCs) improves left ventricular function and remodelling after myocardial infarction.

Zuba-Surma EK, Guo Y, Taher H, Sanganalmath SK, Hunt G, Vincent RJ, Kucia M, Abdel-Latif A, Tang XL, Ratajczak MZ, Dawn B, Bolli R - J. Cell. Mol. Med. (2010)

Impact of cell therapy on cardiomyocyte hypertrophy and LV mass. (A)–(C) Representative images of cardiomyocytes in the viable myocardium from Masson’s trichrome-stained sections of hearts of mice that were given vehicle (group I) (A), expanded and untreated VSEL-SCs (group II) (B) and expanded pre-incubated VSEL-SCs (group III) (C). (D) Quantitative assessment of myocyte cross-sectional area in groups I–III compared with non-infarcted control hearts. (E) Compared with group I, echocardiographically estimated LV mass was significantly less in group III. Data are means ± S.E.M. n= 7–11 mice/group. (E) *P<0.05 versus vehicle (final); #P < 0.05 versus respective baseline values.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3064954&req=5

fig06: Impact of cell therapy on cardiomyocyte hypertrophy and LV mass. (A)–(C) Representative images of cardiomyocytes in the viable myocardium from Masson’s trichrome-stained sections of hearts of mice that were given vehicle (group I) (A), expanded and untreated VSEL-SCs (group II) (B) and expanded pre-incubated VSEL-SCs (group III) (C). (D) Quantitative assessment of myocyte cross-sectional area in groups I–III compared with non-infarcted control hearts. (E) Compared with group I, echocardiographically estimated LV mass was significantly less in group III. Data are means ± S.E.M. n= 7–11 mice/group. (E) *P<0.05 versus vehicle (final); #P < 0.05 versus respective baseline values.
Mentions: Because post-infarct LV remodelling is associated with myocyte hypertrophy and increased LV mass, we investigated the effects of VSEL-SC therapy on these parameters. To this end, we compared the three infarcted groups (groups I–III) with a separate control group (n= 6) of non-infarcted mice that were of similar age (10–12 weeks) and did not undergo surgery. Although the differences did not reach statistical significance, in infarcted mice treated with vehicle (group I) or expanded but not pre-incubated VSEL-SCs (group II), the cross-sectional myocyte area at 35 days after MI (219 ± 21 μm2 and 188 ± 31 μm2 in groups I and II, respectively) was 48% and 27% higher compared with non-infarcted control mice (148 ± 16 μm2). However, in mice given expanded and pre-incubated VSEL-SCs (group III), the myocyte area (147 ± 17 μm2) was virtually identical to that in non-infarcted mice and 30% smaller than that in group I (Fig. 6). These results were corroborated by the echocardiographic estimates of LV mass, which were significantly increased from baseline to 35 days in groups I and II but not in group III; in the latter group, the LV mass was 24% smaller than in group I (P<0.05) (Fig. 6E). Together, these data indicate that transplantation of expanded and pre-incubated VSEL-SCs is associated with attenuation of myocyte hypertrophy.

Bottom Line: In contrast, transplantation of expanded but untreated VSEL-SCs did not produce appreciable reparative benefits.Counter intuitively, the mechanism whereby such pre-incubation confers therapeutic efficacy does not involve differentiation into new cardiac cells.These results support the potential therapeutic utility of VSEL-SCs for cardiac repair.

View Article: PubMed Central - PubMed

Affiliation: Institute of Molecular Cardiology, University of Louisville, Louisville, KY, USA.

Show MeSH
Related in: MedlinePlus